Treatment of sleep-wake disorders

Abstract

This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the ox en atom.

1 - 19 . (canceled) 
     
     
         20 . A method of treating Excessive Daytime Sleepiness (EDS) in a subject, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or ester thereof, wherein
 R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 4 carbon atoms, halogen selected from F C, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
 x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; and 
 R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 4 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms. 
 
     
     
         21 . A method of treating Excessive Daytime Sleepiness (EDS) in a subject, comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates; 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or ester thereof, wherein
 R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 4 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; 
 x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; and 
 R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 4 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms. 
 
     
     
         22 . The method of  claim 21 , wherein the enantiomer of Formula I predominates to the extent of about 90% or greater. 
     
     
         23 . The method of  claim 21 , wherein the enantiomer of Formula I predominates to the extent of about 98% or greater. 
     
     
         24 . The method of  claim 20 , wherein the cause of the EDS is chosen from the group consisting of central nervous system (CNS) pathologic abnormalities, stroke, narcolepsy, idiopathic CNS hypersomnia, sleep deficiency, sleep apnea, obstructive sleep apnea, insufficient nocturnal sleep, chronic pain, acute pain, Parkinson's disease, urinary incontinence, multiple sclerosis fatigue, attention deficit hyperactivity disorder (ADHD), Alzheimer's disorder, major depression, bipolar disorder, cardiac ischemia, misalignments of the body's circadian pacemaker with the environment, jet lag, shift work, and sedating drugs. 
     
     
         25 . The method of  claim 20 , wherein the cause of the EDS is narcolepsy. 
     
     
         26 . The method of  claim 20 , wherein the cause of the EDS is obstructive sleep apnea. 
     
     
         27 . The method of  claim 20 , wherein the cause of the EDS is major depression. 
     
     
         28 . The method of  claim 20 , wherein the therapeutically effective amount is from about 0.01 mg/kg/dose to about 300 mg/kg/dose. 
     
     
         29 . The method of  claim 20 , wherein the therapeutically effective amount is from about 1 mg/day to about 7000 mg/day. 
     
     
         30 . The method of  claim 20 , wherein the enantiomer is administered orally. 
     
     
         31 . The method of  claim 21 , wherein the cause of the EDS is chosen from the group consisting of central nervous system (CNS) pathologic abnormalities, stroke, narcolepsy, idiopathic CNS hypersomnia, sleep deficiency, sleep apnea, obstructive sleep apnea, insufficient nocturnal sleep, chronic pain, acute pain, Parkinson's disease, urinary incontinence, multiple sclerosis fatigue, attention deficit hyperactivity disorder (ADHD), Alzheimer's disorder, major depression, bipolar disorder, cardiac ischemia, misalignments of the body's circadian pacemaker with the environment, jet lag, shift work, and sedating drugs. 
     
     
         32 . The method of  claim 21 , wherein the cause of the EDS is narcolepsy. 
     
     
         33 . The method of  claim 21 , wherein the cause of the EDS is obstructive sleep apnea. 
     
     
         34 . The method of  claim 21 , wherein the cause of the EDS is major depression. 
     
     
         35 . The method of  claim 21 , wherein the therapeutically effective amount is from about 0.01 mg/kg/dose to about 300 mg/kg/dose. 
     
     
         36 . The method of  claim 21 , wherein the therapeutically effective amount is from about 1 mg/day to about 7000 mg/day. 
     
     
         37 . The method of  claim 21 , wherein the compound is administered orally.